Dice (Dexamethasone, Ifosfamide, Cisplatin, Etoposide) as Salvage Therapy in Non-Hodgkin's Lymphomas

References

• Fisher R. I., Gaynor E. R., Dahlberg S., Oken M. M., Grogan T. M., Mize E. M., Glick J. H., Coltman CA, Miller T. P. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New England Journal of Medicine 1993; 328(14)1002–6
   PubMed Web of Science ®Google Scholar
• Merk K., Idestrom K., Johansson B., Kimby E., Lindemalm C., Osby E., Bjorkholm M. Mitoxantrone, etoposide, cytarabine and prednisone as salvage therapy for refractory non-Hodgkin's lymphoma (NHL) and alternated with CHOP in previously untreated patients with NHL. European Journal of Haematology 1991; 46: 33–7
   PubMed Web of Science ®Google Scholar
• Velasquez W. S., Cabanillas F., Salvador P., McLaughlin P., Fridrik M., Tucker S., Jagannath S., Hagemeister F. B., Redman J. R., Swan F. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose ara-C and dexam-ethasone (DHAP). Blood 1988; 71: 117–22
   PubMed Web of Science ®Google Scholar
• Goldie J. H., Coleman A. J. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treatment Reports 1979; 63: 1727–33
   PubMedGoogle Scholar
• Goldie J. H., Goldman A. J., Gudauskas G. A. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treatment Reports 1982; 66: 439–49
   PubMedGoogle Scholar
• Goldie J. H., Coldman A. J. The genetic origin of drug resistance in neoplasms: Implications for systemic therapy. Cancer Research 1984; 44: 3643–53
   PubMed Web of Science ®Google Scholar
• Magrath I., Adde M., Sandlund J., Jain V. Ifosfamide in thee treatment of high-grade recurrent non-Hodgkin's lymphomas. Hematological Oncology 1991; 9(4–5)267–74
   PubMed Web of Science ®Google Scholar
• Rodriguez V., McCredie K. B., Keating M. J. Ifosfamide therapy for hematologic malignancies in patients refractory to prior treatment. Cancer Treatment Reports 1978; 62: 493–7
   PubMedGoogle Scholar
• Stadtmauer E. A., Cassileth P. A., Gale R. P. Etoposide in leukemia, lymphoma and bone marrow transplantation. Leukemia Research 1989; 13: 639–50
   PubMed Web of Science ®Google Scholar
• Rossof A. H., Coltman C. A., Jr., Jones S. E., Talley R. W. Phase II evaluation of cis-dichlorodiammineplatinum (II) in lymphomas: A southwest oncology group study. Cancer Treatment Reports 1979; 63: 9–10
   Google Scholar
• Corder M. P., Wiesenfeld M., Maguire L. C., Leimert J. T., Panther S. K. Cis-dichlorodiammineplatinum (II) with and without ICRF 159 in non-Hodgkin's lymphoma. Cancer Treatment Reports 1980; 64: 301–4
   PubMedGoogle Scholar
• Von Hoff D. D., Elson D. Clinical results with cisplatin in lung cancer. Cisplatin, current status and new developments, A. W. Prestayko, S. Crooke, S. K. Carter. Academic, Orlando, Florida 1980; 445–58
   Google Scholar
• Schabel F. M., Jr., Trader M. W., Laster W. K., Jr., Corbett T. H., Griswold D. P., Jr. Cis-dichloro-diammineplatinum (II): Combination chemotherapy and cross-reference studies with tumors of mice. Cancer Treatment Reports 1979; 63: 1459–73
   PubMedGoogle Scholar
• Kroner T., Obrecht J. P., Jungi W. F. Etoposide as single agent and in combination with cis-platinum for malignant lymphomas. Cancer Treatment Reviews 1982; 9: 39–43, (Suppl A)
   PubMed Web of Science ®Google Scholar
• von Heyden H. W., Scherpe A., Nagel G. A. Cis-dichlore-diammine-platinum (II) (cis-platinum) and etoposide for refractory lymphomas. Cancer Treatment Reviews 1982; 9: 45–52, (Suppl A)
   PubMed Web of Science ®Google Scholar
• Goss P. E., Shepherd F. A., Scott J. G., Warner E., Baker M. A., Sutton D., Farquharson H. A., Buick S., Sutcliffe S. Dexamethasone/ifosfamide/cisplatin/etoposide (DICE) as therapy for patients with advanced refractory non-Hodgkin's lymphoma: Preliminary report of a phase II study. Annols of Oncology 1991; 2: 43–46
   PubMed Web of Science ®Google Scholar
• Vitolo U., Orsucci L., Bertini M., Cavallero G., Gallamini A., Ghio R., Levis A., Rota-Scalabrini D., Resegotti L. Mitoxantrone, etoposide, cisplatin and dexamethasone (MEPD) as salvage chemotherapy in resistant non-Hodgkin's lymphoma. Haematologica 1991; 76(1)43–46
   PubMedGoogle Scholar
• Rapoport A. P., Rowe J. M., Kouides P. A., Duerst R. A., Abboud C. N., Liesveld J. L., Packman C. H., Eberly S., Sherman M., Tanner M. A. One hundred autotransplants for rel-pased or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. Journal of Clinical Oncology 1993; 11: 2351–61
   PubMed Web of Science ®Google Scholar
• Cabanillas F., Hagemieister F. B., McLaughlin P. Results of MIME salvage regimen for recurrent or refractory lymphoma. Journal, of Clinical Oncology 1987; 5: 407–12
   PubMed Web of Science ®Google Scholar
• Heinz R., Dittric H., Ludwig H. Results of a new drug combination (VP-16-Ifosfamide-Mitoxantrone-Bleomycin (VIM-BLEO) in advanced non-Hodgkin's lymphomas. Contr. Oncol. (Karger, Basel) 1987; 26: 438–45
   Google Scholar
• Dovey G. J., Child J. A., Simmons A. V., Barnard D. L., Parapia L., Morgan M., Fletcher J., Parker D., Norfolk D. R., Stone J. Hematological Oncology 1990; 8(4)205–13
   PubMed Web of Science ®Google Scholar
• Cabanillas F. Ifosfamide combinations in lymphoma. Seminars in Oncology 1990; 17: 58–62, (Suppl 4)
   PubMed Web of Science ®Google Scholar
• Haim N., Rosenblatt E., Wollner M., Ben-Shahar M., Epelbaum R., Robinson E. Salvage therapy for non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide and cisplatin. Cancer Chemotherapy & Pharmacology 1992; 30(3)243–44
   PubMed Web of Science ®Google Scholar
• Rybak M. E., Anderson J., Kaplan R, Budman D. R., Vinciguerra V., Gottlieb A. J. Phase II trial of etoposide and cisplatin in patients with refractory and relapsed non-Hodgkin's lymphoma: Cancer and Leukemia Group B study 8351. Medical and Pediatric Oncology 1993; 21(6)441–45
   PubMedGoogle Scholar
• Bezwoda W. R., Bezwoda M. A., Seymour L., Dansey R., Ariad S. NOPE for relapsed aggressive diffuse non-Hodgkin's lymphoma. Leukemia & Lymphoma 1993; 10(4–5)329–33
   PubMed Web of Science ®Google Scholar
• Neidhart J. A., Kubica R., Stidley C., Pfile J., Clark D., Rinehart J. Multiple cycles of dose-intensive cyclophos-phamide, etoposide, and cisplatin (DICEP) produce durable responses in refractory non-Hodgkin's lymphoma. Cancer Investigation 1994; 12(1)1–11
   PubMed Web of Science ®Google Scholar